Exelixis (EXEL) Depreciation & Amortization (CF) (2010 - 2026)
Exelixis (EXEL) posted quarterly Depreciation & Amortization (CF) of $6.9 million for Q2 2026, down 5.41% year-over-year from $7.3 million in Q2 2025, and little changed quarter-over-quarter from $6.9 million in Q1 2026.
Analysis
Exelixis (EXEL) Depreciation & Amortization (CF) (2010 - 2026) Analysis & Trends
Exelixis' Depreciation & Amortization (CF) history runs 17 years deep, the most recent figure standing at $6.9 million for Q2 2026.
- In Q2 2026, Depreciation & Amortization (CF) fell 5.41% year-over-year to $6.9 million; the TTM figure through Apr 2026 stood at $28.7 million (down 3.74% YoY), while the FY2026 annual figure was $29.1 million, up 0.87% from the prior year.
- Depreciation & Amortization (CF) for Q2 2026 stood at $6.9 million, roughly flat from $6.9 million in the prior quarter.
- The five-year high for Depreciation & Amortization (CF) was $7.6 million in Q1 2025, with the low at $4.5 million in Q2 2022.
- The 5-year median for Depreciation & Amortization (CF) is $6.9 million (2023), against an average of $6.6 million.
- The sharpest annual moves came in 2022 and 2026: Depreciation & Amortization (CF) soared 207.92% in 2022, then dropped 9.11% in 2026.
- Exelixis' Depreciation & Amortization (CF) stood at $5.9 million in 2022, then grew by 9.75% to $6.5 million in 2023, then gained by 14.22% to $7.5 million in 2024, then fell by 0.43% to $7.4 million in 2025, then declined by 6.39% to $6.9 million in 2026.
- Business Quant data shows EXEL's Depreciation & Amortization (CF) at $6.9 million in Q2 2026, $6.9 million in Q1 2026, and $7.4 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 40.52 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Exelixis | 14.81 Bn | 13.97 Bn | 608.03 Mn | 6.98 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 6.98 Mn |
| Apr 3, 2026 | 6.95 Mn |
| Jan 2, 2026 | 6.95 Mn |
| Oct 3, 2025 | 7.42 Mn |
| Jul 4, 2025 | 7.34 Mn |
| Apr 4, 2025 | 7.35 Mn |
| Jan 3, 2025 | 7.64 Mn |
| Sep 27, 2024 | 7.45 Mn |
| Jun 28, 2024 | 7.33 Mn |
| Mar 29, 2024 | 6.38 Mn |
| Dec 29, 2023 | 6.53 Mn |
| Sep 29, 2023 | 6.30 Mn |
| Jun 30, 2023 | 6.04 Mn |
| Mar 31, 2023 | 6.86 Mn |
| Dec 30, 2022 | 5.95 Mn |
| Sep 30, 2022 | 5.66 Mn |
| Jul 1, 2022 | 4.78 Mn |
| Apr 1, 2022 | 4.49 Mn |
| Dec 31, 2021 | 1.93 Mn |
| Oct 1, 2021 | 4.80 Mn |